Literature DB >> 31342317

H3K27 trimethylation loss in malignant peripheral nerve sheath tumor: a systematic review and meta-analysis with diagnostic implications.

Victor M Lu1, Tomas Marek2, Hannah E Gilder2, Ross C Puffer2, Aditya Raghunathan3, Robert J Spinner2, David J Daniels4.   

Abstract

BACKGROUND: Multiple studies have reported the loss of trimethylation at lysine (K) 27 on histone 3 (H3K27me3) in high-grade malignant peripheral nerve sheath tumors (MPNSTs). However, the diagnostic potential of this finding in MPNSTs remains yet to be fully substantiated. Correspondingly, our aim was to pool systematically-identified metadata in the literature and substantiate the incidence of H3K27me3 loss in this setting.
METHODS: Searches of 7 electronic databases from inception to May 2019 were conducted following PRISMA guidelines. Articles were screened against pre-specified criteria. The incidence of loss was then pooled by random-effects meta-analysis of proportions.
RESULTS: Nine pertinent studies described a total of 823 high-grade MPNST samples. When pooled, incidence (sensitivity) of complete H3K27me3 loss was estimated to be 53% (95% CI 42-64%). For MPNST subtypes, estimated incidences of complete loss in NF1 subtype was 52% (95% CI 41-62), in sporadic subtype was 53% (95% CI 36-70%), in the epithelioid subtype was 0% (95% CI 0-7%), and radiation-associated subtype was 98% (95% CI 86-100%). Finally, incidence of incomplete loss (specificity) in 1231 MPNST-mimic samples was estimated to be 96% (95% CI 90-99%). Certainty of these outcomes ranged from very low to high.
CONCLUSIONS: The incidence of complete H3K27me3 loss is substantial in high-grade MPNSTs and is low in MPNST-mimics. Greater cohort study and biological investigation will validate the certainty of these findings as well as elucidate their true molecular and clinical significances.

Entities:  

Keywords:  H3K27me3; Lysine; MPNST; Malignant peripheral nerve sheath tumor; Sensitivity; Trimethylation

Mesh:

Substances:

Year:  2019        PMID: 31342317     DOI: 10.1007/s11060-019-03247-3

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  6 in total

Review 1.  Practical Approach to Histological Diagnosis of Peripheral Nerve Sheath Tumors: An Update.

Authors:  Gaetano Magro; Giuseppe Broggi; Giuseppe Angelico; Lidia Puzzo; Giada Maria Vecchio; Valentina Virzì; Lucia Salvatorelli; Martino Ruggieri
Journal:  Diagnostics (Basel)       Date:  2022-06-14

Review 2.  Transition of a vestibular schwannoma to a malignant peripheral nerve sheath tumor with loss of H3K27 trimethylation after radiosurgery-a case report and review of the literature.

Authors:  Felix Behling; Imane Bersali; Antonio Santacroce; Johann Hempel; Kosmas Kandilaris; Jens Schittenhelm; Marcos Tatagiba
Journal:  Neurosurg Rev       Date:  2021-08-15       Impact factor: 2.800

3.  Histopathologic findings in malignant peripheral nerve sheath tumor predict response to radiotherapy and overall survival.

Authors:  Calixto-Hope G Lucas; Harish N Vasudevan; William C Chen; Stephen T Magill; Steve E Braunstein; Line Jacques; Sonika Dahiya; Fausto J Rodriguez; Andrew E Horvai; Arie Perry; Melike Pekmezci; David R Raleigh
Journal:  Neurooncol Adv       Date:  2020-10-01

4.  H3K27me3 loss indicates an increased risk of recurrence in the Tübingen meningioma cohort.

Authors:  Felix Behling; Christina Fodi; Irina Gepfner-Tuma; Kristina Kaltenbach; Mirjam Renovanz; Frank Paulsen; Marco Skardelly; Jürgen Honegger; Marcos Tatagiba; Jens Schittenhelm; Ghazaleh Tabatabai
Journal:  Neuro Oncol       Date:  2021-08-02       Impact factor: 12.300

5.  Loss of H3K27me3 expression in canine nerve sheath tumors.

Authors:  Kristina Tekavec; Tanja Švara; Tanja Knific; Jernej Mlakar; Mitja Gombač; Carlo Cantile
Journal:  Front Vet Sci       Date:  2022-07-29

Review 6.  Mediastinal sarcomas: experience using fine needle aspiration cytopathology.

Authors:  Abberly A Lott-Limbach; Paul E Wakely
Journal:  Mediastinum       Date:  2020-06-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.